This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.

4nwu

From Proteopedia

(Difference between revisions)

Jump to: navigation, search

Current revision

Crystal structure of APE1551, an anti-human NGF Fab with a nine amino acid insertion in CDR H1

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/4nwu"

Categories: Homo sapiens | Large Structures | Stanfield RL | Verdino P | Wilson IA

@@ Line 3: / Line 3: @@
 <StructureSection load='4nwu' size='340' side='right'caption='[[4nwu]], [[Resolution|resolution]] 1.60&Aring;' scene=''>
 == Structural highlights ==
-<table><tr><td colspan='2'>[[4nwu]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4NWU OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4NWU FirstGlance]. <br>
+<table><tr><td colspan='2'>[[4nwu]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4NWU OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4NWU FirstGlance]. <br>
-</td></tr><tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">IGHG1 ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
+</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.602&#8491;</td></tr>
 <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4nwu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4nwu OCA], [https://pdbe.org/4nwu PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4nwu RCSB], [https://www.ebi.ac.uk/pdbsum/4nwu PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4nwu ProSAT]</span></td></tr>
 </table>
-<div style="background-color:#fffaf0;">
+== Disease ==
-== Publication Abstract from PubMed ==
+[https://www.uniprot.org/uniprot/IGHG1_HUMAN IGHG1_HUMAN] Defects in IGHG1 are a cause of multiple myeloma (MM) [MIM:[https://omim.org/entry/254500 254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving IGHG1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus. Translocation t(11;14)(q13;q32) with CCND1; translocation t(4;14)(p16.3;q32.3) with FGFR3; translocation t(6;14)(p25;q32) with IRF4.
-During somatic hypermutation (SHM), deamination of cytidine by activation-induced cytidine deaminase (AID) and subsequent DNA repair generates mutations within immunoglobulin V-regions. Nucleotide insertions and deletions (indels) have recently been shown to be critical for the evolution of antibody binding. Affinity maturation of 53 antibodies using in vitro SHM in a non-B cell context was compared with mutation patterns observed for SHM in vivo. The origin and frequency of indels seen during in vitro maturation was similar to that in vivo. Indels are localized to CDRs, and secondary mutations within insertions further optimize antigen binding. Structure determination of an antibody matured in vitro and comparison with human-derived antibodies containing insertions reveals conserved patterns of antibody maturation. These findings indicate that AID acting on V region sequences is sufficient to initiate authentic formation of indels in vitro and in vivo, and that point mutations, indel formation and clonal selection form a robust, tripartite system for antibody evolution.
+== Function ==
+[https://www.uniprot.org/uniprot/IGHG1_HUMAN IGHG1_HUMAN]
-Nucleotide insertions and deletions complement point mutations to massively expand the diversity created by somatic hypermutation of antibodies.,Bowers PM, Verdino P, Wang Z, da Silva Correia J, Chhoa M, Macondray G, Do M, Neben TY, Horlick RA, Stanfield RL, Wilson IA, King DJ J Biol Chem. 2014 Oct 15. pii: jbc.M114.607176. PMID:25320089<ref>PMID:25320089</ref>
-From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-</div>
-<div class="pdbe-citations 4nwu" style="background-color:#fffaf0;"></div>
-== References ==
-<references/>
 __TOC__
 </StructureSection>
-[[Category: Human]]
+[[Category: Homo sapiens]]
 [[Category: Large Structures]]
-[[Category: Stanfield, R L]]
+[[Category: Stanfield RL]]
-[[Category: Verdino, P]]
+[[Category: Verdino P]]
-[[Category: Wilson, I A]]
+[[Category: Wilson IA]]
-[[Category: Beta-sandwich]]
-[[Category: Human beta nerve growth factor]]
-[[Category: Immune system]]

4nwu

From Proteopedia

Current revision

Crystal structure of APE1551, an anti-human NGF Fab with a nine amino acid insertion in CDR H1

Structural highlights

Disease

Function

Contents

Proteopedia Page Contributors and Editors (what is this?)

Views

Personal tools

Navigation

Search

Toolbox